1-6 of 6
Anupa Kudva
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Clinical Trials & Observations
Jesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A. Dimopoulos, Thierry Facon, María-Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis
Journal: Blood
Blood (2022) 139 (4): 492–501.
https://doi.org/10.1182/blood.2020010439
Published: 2022
Includes: Supplemental data
Journal Articles

Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM)

Niels W. C. J. van de Donk, Sonja Zweegman, MDPhD, Jesus F. San-Miguel, MD PhD, Meletios A Dimopoulos, Michele Cavo, Kenshi Suzuki, MD PhD, Cyrille Touzeau, Saad Z. Usmani, MDMBBS,MBA, Aurore Perrot, Huiling Pei, PhD, Anupa Kudva, MD, Rian Van Rampelbergh, Jon Ukropec, PhD, Kevin Leary, Robin Carson, MD BA, Ming Qi, MD PhD, Ajai Chari
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-134923
Published: 2020
Journal Articles

Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Paula Rodriguez-Otero, Mario Boccadoro, Roman Hajek, MD, Tomoaki Fujisaki, MD, Jae Hoon Lee, MD PhD, Joaquin Martinez-Lopez, MD, Paulo Lucio, MD PhD, Zsolt Nagy, MD PhD, Ganna Usenko, MD, Anna Marina Liberati, MD, Mihaela Lazaroiu, MD, Dariusz Woszczyk, MDPhD, Hiroyuki Takamatsu, MDPhD, Joanna Romejko-Jarosinska, Stefan Tobias Knop, Astrid Pavlovsky, MD, Cecily Forsyth, FRACP, FRCPA, MBBS, Takayuki Ishikawa, MD PhD, Katharine S. Gries, PhD PharmD, Huiling Pei, PhD, Anupa Kudva, MD, Jon Ukropec, PhD, Susan Wroblewski, PhD, Robin Carson, MD BA, Meletios A Dimopoulos
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-136145
Published: 2020
Journal Articles

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Jesus F. San-Miguel, MD PhD, Herve Avet-Loiseau, Bruno Paiva, PhD, Shaji K. Kumar, MD, Meletios A. Dimopoulos, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Cyrille Touzeau, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MDMBBS,MBA, Gordon Cook, MD, Michele Cavo, Hang Quach, MDFRACP,FRCPA,MBBS, Jon Ukropec, PhD, Priya Ramaswami, Huiling Pei, PhD, Steven Sun, Jianping Wang, Maria Krevvata, PhD, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, MD, Rachel Kobos, MD, Ming Qi, MD PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-134928
Published: 2020
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Maria-Victoria Mateos, Michele Cavo, Joan Bladé, MD PhD, Meletios A. Dimopoulos, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, MD PhD, Zsolt Nagy, MD PhD, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, MD FRCP, FRCPath, Maria Krevvata, PhD, Jianping Wang, Anupa Kudva, MD, Jon Ukropec, PhD, Susan Wroblewski, PhD, Rachel Kobos, MD, Jesús San-Miguel
Journal: Blood
Blood (2019) 134 (Supplement_1): 859.
https://doi.org/10.1182/blood-2019-123401
Published: 2019
Journal Articles

One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

Meletios A Dimopoulos, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, Zsolt Nagy, MD PhD, Polina Kaplan, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, MD, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, Christopher Chiu, PhD, Jianping Wang, Anupa Kudva, Rachel Kobos, MD, Susan Wroblewski, PhD, Ming Qi, MD PhD, Jesus F San-Miguel, MD PhD, Joan Bladé, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 156.
https://doi.org/10.1182/blood-2018-156
Published: 2018